Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-3792 and HRS-9190

Fineline Cube Apr 14, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received separate...

Company Drug

Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer

Fineline Cube Apr 14, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...

Company Drug

Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma

Fineline Cube Apr 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from...

Company Drug

CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin

Fineline Cube Apr 14, 2025

China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received...

Company

Novartis Announces USD 23 Billion Investment to Expand U.S. Manufacturing and R&D Hubs

Fineline Cube Apr 11, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced plans to invest USD 23 billion over...

Company Drug

Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA

Fineline Cube Apr 11, 2025

Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...

Company Drug

Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy

Fineline Cube Apr 11, 2025

China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...

Company Drug

Zai Lab’s Partner argenx Secures FDA Approval for Vygart Hytrulo Prefilled Syringe in gMG and CIDP

Fineline Cube Apr 11, 2025

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) and its Dutch partner argenx SE (NASDAQ:...

Company Deals

Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology

Fineline Cube Apr 11, 2025

France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG...

Company Deals Medical Device

INTCO Medical and JD Healthcare Partner to Innovate ‘Internet + Healthcare’ Service Models

Fineline Cube Apr 11, 2025

China-based INTCO Medical (SHE: 300677), a high-tech manufacturer of medical consumables and equipment, has entered...

Company Medical Device

KingstronBio’s Prostyle A Valve Gains NMPA Approval, Setting New Benchmark in Transcatheter Aortic Valve Replacement

Fineline Cube Apr 11, 2025

KingstronBio, a Changshu-based structural heart disease device manufacturer, has obtained marketing approval from China’s National...

Company Deals

iRegene Therapeutics Secures RMB 100 Million in Series B+ Financing to Advance iPSC Technology

Fineline Cube Apr 11, 2025

Wuhan-based iRegene Therapeutics, a pioneer in AI-powered, chemically induced cell therapies, has reportedly raised close...

Company

Novo Nordisk Invests BRL 6.4 Billion in Brazilian Manufacturing Expansion for Obesity Drugs

Fineline Cube Apr 11, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion...

Company Drug

Jemincare Group Announces NMPA Approval of Generic Clenil for Asthma Treatment

Fineline Cube Apr 11, 2025

China-based Jiangxi Jemincare Group has announced that it has received marketing approval from the National...

Company Deals

Nona Biosciences and Atossa Therapeutics Forge Partnership to Advance Breast Cancer Therapies

Fineline Cube Apr 11, 2025

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Bayer’s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors

Fineline Cube Apr 11, 2025

Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food...

Company Drug

Luye Pharma Launches Rotigotine Luye in UK for Parkinson’s and Restless Leg Syndrome

Fineline Cube Apr 11, 2025

China-based Luye Pharma Group (HKG: 2186) announced the market launch of Rotigotine Luye in the...

Company Deals

Astellas Pharma Partners with Shanghai Pharma on Zolbetuximab Commercialization

Fineline Cube Apr 11, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) announced a strategic partnership with Shanghai Pharmaceuticals (SPH; SHA:...

Company Drug

CK Life Sciences Reports Promising Preclinical Results for TROP2-Targeted Cancer Vaccine

Fineline Cube Apr 11, 2025

China-based CK Life Sciences (HKG: 0775) has announced positive early results from preclinical studies of...

Company Drug

Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials

Fineline Cube Apr 10, 2025

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient...

Posts pagination

1 … 115 116 117 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.